GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Kyverna Therapeutics Inc (NAS:KYTX) » Definitions » Pretax Margin %

KYTX (Kyverna Therapeutics) Pretax Margin % : % (As of Dec. 2024)


View and export this data going back to 2024. Start your Free Trial

What is Kyverna Therapeutics Pretax Margin %?

Pre-Tax margin is calculated as Pre-Tax Income divided by its Revenue. Kyverna Therapeutics's Pre-Tax Income for the three months ended in Dec. 2024 was $-37.49 Mil. Kyverna Therapeutics's Revenue for the three months ended in Dec. 2024 was $0.00 Mil. Therefore, Kyverna Therapeutics's pretax margin for the quarter that ended in Dec. 2024 was %.

The historical rank and industry rank for Kyverna Therapeutics's Pretax Margin % or its related term are showing as below:


KYTX's Pretax Margin % is not ranked *
in the Biotechnology industry.
Industry Median: -127.47
* Ranked among companies with meaningful Pretax Margin % only.

Kyverna Therapeutics Pretax Margin % Historical Data

The historical data trend for Kyverna Therapeutics's Pretax Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Kyverna Therapeutics Pretax Margin % Chart

Kyverna Therapeutics Annual Data
Trend Dec21 Dec22 Dec23 Dec24
Pretax Margin %
-465.88 -411.29 - -

Kyverna Therapeutics Quarterly Data
Dec21 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24
Pretax Margin % Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - -

Competitive Comparison of Kyverna Therapeutics's Pretax Margin %

For the Biotechnology subindustry, Kyverna Therapeutics's Pretax Margin %, along with its competitors' market caps and Pretax Margin % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Kyverna Therapeutics's Pretax Margin % Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Kyverna Therapeutics's Pretax Margin % distribution charts can be found below:

* The bar in red indicates where Kyverna Therapeutics's Pretax Margin % falls into.


;
;

Kyverna Therapeutics Pretax Margin % Calculation

Pretax margin - also known as pretax profit margin is the ratio of Pretax Income divided by net sales or Revenue, usually presented in percent.

Kyverna Therapeutics's Pretax Margin for the fiscal year that ended in Dec. 2024 is calculated as

Pretax Margin=Pre-Tax Income (A: Dec. 2024 )/Revenue (A: Dec. 2024 )
=-127.477/0
= %

Kyverna Therapeutics's Pretax Margin for the quarter that ended in Dec. 2024 is calculated as

Pretax Margin=Pre-Tax Income (Q: Dec. 2024 )/Revenue (Q: Dec. 2024 )
=-37.489/0
= %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Kyverna Therapeutics  (NAS:KYTX) Pretax Margin % Explanation

The pretax margin, as know as pretax profit margin, is widely used to measure the operating efficiency of a company before deducting taxes.

The pretax margin is sometimes preferred over the net margin as tax expenditures can make profitability comparisons between companies misleading.

It is a useful tool to compare companies operating in the same sector and less effective when comparing companies from other sectors as each industry generally has different operating expenses and sales patterns.

The long term trend of the pretax margin is a good indicator of the competitiveness and health of the business.


Kyverna Therapeutics Pretax Margin % Related Terms

Thank you for viewing the detailed overview of Kyverna Therapeutics's Pretax Margin % provided by GuruFocus.com. Please click on the following links to see related term pages.


Kyverna Therapeutics Business Description

Traded in Other Exchanges
N/A
Address
5980 Horton Street, Suite 550, Emeryville, CA, USA, 94608
Kyverna Therapeutics Inc is a clinical-stage biopharmaceutical company. The company is focused on developing cell therapies for patients suffering from autoimmune diseases. Its product, KYV-101, is an autologous CD19 CAR T-cell product candidate made from an underlying chimeric antigen receptor, or CAR. It is also developing KYV-201, an allogeneic therapy containing the same CAR as KYV-101, to develop it in multiple autoimmune diseases.

Kyverna Therapeutics Headlines

From GuruFocus